DARZALEX® Clinical Studies:

DARZALEX® in combination with Velcade® 
(bortezomib) + melphalan + prednisone

DARZALEX® was studied in combination with Velcade®, melphalan, and prednisone (VMP) vs VMP alone in 706 people with newly diagnosed multiple myeloma who could not receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).

The main goal of the study was to measure the length of time people lived without their multiple myeloma getting worse or passing away from any cause. Another goal was to measure overall response rate, which is the percentage of people who responded to treatment.

Clinical trial results: DARZALEX® + VMP vs VMP alone

DARZALEX® in combination with VMP increased the time people lived without their multiple myeloma getting worse or passing away from any cause

  • 50% less risk of disease progression or passing away with DARZALEX® in combination with VMP vs VMP alone

At a median follow-up of 16.5 months, 25% of patients treated with D+VMP had disease progression or passed away vs 40% of patients treated with VMP alone.

More people responded to DARZALEX® in combination with VMP vs VMP alone

9 out of 10 people
responded to DARZALEX® + Velcade® + melphalan + prednisone vs 7 out of 10 people with Velcade® + melphalan + prednisone